Ryoncil® product information now available in all four major drug pricing compendia in united states

New york, march 13, 2025 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that pricing information for ryoncil® is now available in all four major drug pricing compendia in the united states. these pricing compendia provide the official source for all information required to order product, including product manufacturing details, national drug codes (ndc) for kit purchase, and kit pricing.
MESO Ratings Summary
MESO Quant Ranking